Inhibition of RAS delays onset of diabetes in clinical studies. Preliminary evidence suggests
that telmisartan may have unique metabolic properties compared to other ARB due to activation
of PPARĪ³.
This should be tested in comparison with an ARB that is metabolically neutral in already
published studies.
H0: Telmisartan is not different from Losartan with respect to metabolic and vascular
effects.
H1: Telmisartan is different from Losartan with respect to metabolic and vascular effects.